News | October 07, 2023
Amgen completes acquisition of Horizon Therapeutics
Advances Amgen's mission to serve patients with rare disease medicines
Advances Amgen's mission to serve patients with rare disease medicines
As Caeregen’s CDMO partner for CTR-107, Wacker Biotech will produce drug substance at its site in Halle, Germany, and complete clinical trial drug product production at its site in Amsterdam, the Netherlands
Chinook Therapeutics is a clinical-stage biopharmaceutical company with two high-value, late-stage assets in development for IgA nephropathy (IgAN), a rare, progressive chronic kidney disease
Aim of the agreement is to expand the full potential of Beren’s cyclodextrin technologies and their medicinal applications.
APP13007 is a novel aqueous nanosuspension formulation for the treatment of inflammation and pain following ocular surgery
WuXi Bio provided technical services, based on the companies' versatile integrated service platforms, to support various manufacturing and process development activities of these ADC product candidates.
ProBioGen previously developed the cell line and the manufacturing process and provided the initial clinical material for ImmunOs' innovative biologic.
The one-year-long study was aimed to evaluate the efficacy of LDH's digital therapeutics platform
The collaboration will focus on developing a localized and sustained-release drug delivery system for oncology patients
Clinical studies are expected to start in Q2 2023.
Subscribe To Our Newsletter & Stay Updated
